William Blair & Company
SRPT icon

William Blair & Company’s Sarepta Therapeutics SRPT Stock Holding History

William Blair & Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-100
Closed -$7K – 1633
2018
Q1 		$7K Hold
100
– – ﹤0.01% 1474
2017
Q4 		$6K Buy
+100
New +$5.3K ﹤0.01% 1360

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair & Company's SRPT Position: Q1 2026 in Review

William Blair & Company reduced its Sarepta Therapeutics (SRPT) stake by 2.4% in Q1 2026, selling an estimated $12.4K and leaving 25,690 shares worth $559K. The position accounts for ﹤0.01% of the portfolio, ranked #1115.

William Blair & Company first reported a position in SRPT in Q2 2013 and has held it in 40 quarters since. The position peaked at $27.5M in Q2 2024. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • William Blair & Company held 25,690 shares of Sarepta Therapeutics worth $559K as of Q1 2026.
  • William Blair & Company sold 643 Sarepta Therapeutics shares in Q1 2026, an estimated $12.4K.
  • Sarepta Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1115 holding.
  • William Blair & Company first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • William Blair & Company's Sarepta Therapeutics position peaked at $27.5M in Q2 2024.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.